ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2026.01.009
Clinical Significance of Adiponectin in Patients with Coronary Heart Disease and Atrial Fibrillation
Biling Ye1,*, Qing Liao1, Nan Zhang2, Yuanfang Ouyang3
1Department of Quality Management and Public Health, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen 518067, Guangdong, China.
2Department of Gynecology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen 518067, Guangdong, China.
3Department of Cardiology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen 518067, Guangdong, China.
*Corresponding author: Biling Ye
Published: January 25,2026
Abstract
Objective: This study aimed to investigate the clinical significance of serum adiponectin (APN) levels in patients with coronary heart disease (CHD) complicated by atrial fibrillation (AF). Methods: A total of 96 patients admitted between January 2023 and January 2024 were enrolled and divided into a CHD group (n = 48) and a CHD + AF group (n = 48) according to the presence of AF. Serum APN levels were measured in both groups, and their relationships with cardiac function indices, inflammatory markers, and prognosis were analyzed. Results: Serum adiponectin levels in the CHD + AF group were significantly lower than those in the CHD group (P < 0.05). Serum APN levels were positively correlated with left ventricular ejection fraction (LVEF) (r = 0.512, P < 0.05) and negatively correlated with high-sensitivity C-reactive protein (hs-CRP) (r = −0.487, P < 0.05) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (r = −0.536, P < 0.05). Conclusion: Serum APN may serve as a potential biomarker for assessing disease severity and prognosis in patients with CHD complicated by AF.
Keywords
Adiponectin; Coronary heart disease; Atrial fibrillation; Clinical monitoring
References
[1] Wei ZL. Effects of Tianwang Buxin Tablets combined with atorvastatin on inflammatory factors and cardiac function in elderly patients with coronary heart disease complicated by atrial fibrillation. Clin Rational Drug Use. 2023;16(14):61-64.
[2] Zhang JH, Wang SN, Zhao RP, et al. Predictive value of serum NEUT, Hcy, adiponectin, and blood glucose for acute myocardial infarction in patients with coronary heart disease. Public Health Prev Med. 2025;36(5):97-101.
[3] Tian CY, Liu NN. Predictive value of combined detection of serum CRP, Hcy, and adiponectin for prognosis in patients with coronary heart disease undergoing interventional therapy. Clin Med Eng. 2024;31(7):837-838.
[4] Xu P, Guo JJ, Wu L. Clinical efficacy of sacubitril/valsartan in the treatment of coronary heart disease complicated by chronic heart failure and its effects on cardiac function. Clin Rational Drug Use. 2025;18(26):39-42.
[5] Ren YY, Cheng G, Zhao T. Relationship between serum adiponectin, omentin-1, and coronary artery calcification and its severity in patients with coronary heart disease. J Pract Cardio-Cerebrovasc Dis. 2025;33(1):39-43.
[6] Wang C, Chen XH, Fu QA. Prognostic value of adipocyte fatty acid-binding protein combined with adiponectin in patients with coronary heart disease. J Pract Cardio-Cerebrovasc Dis. 2024;32(8):19-22.
[7] Du YH, Duan CL, Wei Y, et al. Study on the correlation between plasma neurotransmitters and qi deficiency and blood stasis syndrome in patients with coronary heart disease complicated with atrial fibrillation. Chin J Emerg Tradit Chin Med. 2025;34(2):211-214.
[8] Wei SS, Song QQ, Zhao SC, et al. Study on the comorbidity mechanism and core traditional Chinese medicine prediction of coronary heart disease with atrial fibrillation. J Basic Med Tradit Chin Med. 2025;31(11):2004-2011.
How to cite this paper
Clinical Significance of Adiponectin in Patients with Coronary Heart Disease and Atrial Fibrillation
How to cite this paper: Biling Ye, Qing Liao, Nan Zhang, Yuanfang Ouyang. (2026) Clinical Significance of Adiponectin in Patients with Coronary Heart Disease and Atrial Fibrillation. International Journal of Clinical and Experimental Medicine Research, 10(1), 38-41.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.01.009